Special Issue "Pharmaceutic Formulas for Radiation Therapy Enhancement"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Clinical Pharmaceutics".

Deadline for manuscript submissions: closed (10 August 2023) | Viewed by 252

Special Issue Editors

“Horia Hulubei” National Insitute of Physics and Nuclear Engineering (IFIN-HH), 30 Reactorului Street, 077125 Magurele, Romania
Interests: nanobiomaterials; drug delivery; cancer therapy; radiobiology; biocompatibility
Special Issues, Collections and Topics in MDPI journals
Department of Life and Environmental Physics, Horia Hulubei National Institute of Physics and Nuclear Engineering, 077125 Magurele, Romania
Interests: radioresistant cancer cell biology; tumor cell radiosensitization; DNA damage signaling; mitochondria–nucleus communication; radiation-induced bystander effects; radiation response biomarkers; tumor microenvironment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to a Special Issue of Pharmaceutics entitled “Pharmaceutic formulas for radiation therapy enhancement”. Nowadays the curative approaches for cancer management include a form of radiation therapy in order to reduce the metabolism and growth of tumor cells. Different kinds of radiation have been applied in order to deposit a higher dose at the malignant site and to reduce the adverse effects of the surrounding tissues.

In order to increase the cytotoxic effects of radiation therapy in the tumor cells and to reduce the damage provoked to the normal cells in the immediate vicinity, different pharmaceutic approaches have been applied, starting from drugs, different molecules that are able to interfere with the signaling and metabolic processes of the cancerous cells, high Z (nano-)materials, magnetic (nano-)materials, etc.

This Special Issue aims to cover recent advancements in radiation-based therapeutic approaches used for the management of cancer, addressing either preclinical in vitro and in vivo testing, clinical approaches or in silico testing.  

We look forward to receiving your contributions.

Dr. Roxana Cristina Popescu
Dr. Diana Savu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • radiation therapy
  • cancer therapy
  • pharmaceutic formulas
  • radiosensitization
  • preclinical testing
  • clinical testing

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop